@Article{Wasilewska2016,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="33",
number="4",
year="2016",
title="Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases",
abstract="Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment – a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).",
author="Wasilewska, Agnieszka
and Winiarska, Marta
and Olszewska, Małgorzata
and Rudnicka, Lidia",
pages="247--252",
doi="10.5114/ada.2016.61599",
url="http://dx.doi.org/10.5114/ada.2016.61599"
}